18 Feb 22 | Celltrion released two data sets on the subcutaneous (SC) form of Remsima® (biosimilar infliximab). Celltrion reported that switching from IV to SC infliximab leads...
Pearce IP BioBlast w/e 25 February 2022
read more
Why Preparedness Is So Pivotal
In this Boutique Lawyer Show podcast, Pearce IP’s CEO and Executive Naomi Pearce speaks candidly with Lawyers Weekly’s Jerome Doraisamy.
Nothing inventive in the electronic operation and configuration of fitness studios
F45 Training Pty Ltd v Body Fit Training Company Pty Ltd (No 2) [2022] FCA 96 Date:Court:Judge:15 February 2022Federal Court of AustraliaNicholas JBackground F45 Training Pty Ltd...
Pearce IP BioBlast 18 February 2022
11 Apr 22 | CA | Celltrion announced the launch of Yuflyma® (high-concentration, low-volume, citrate-free and latex-free biosimilar adalimumab) in Canada. Yuflyma® is approved...
Interlocutory injunction to restrain further threats of patent infringement granted in car park scrap
UbiPark Pty Ltd v TMA Capital Australia Pty Ltd [2022] FCA 111 Date:Court:Judge:14 February 2022Federal Court of AustraliaMohinsky JBackground UbiPark Pty Ltd (UbiPark) and...
PTE alert: Patent Office cancellation of PTE paves the way for potential launch of generic YASMIN products
We have previously reported on a number of Federal Court decisions in 2021 invalidating patent term extensions (PTEs) in Australia: Biogen International GmbH v Pharmacor Pty Ltd...
Pearce IP BioBlast w/e 11 February 2022
07 Feb 22 | The International Generic and Biosimilar medicines Association (IGBA) announced that it has established a CEO Advisory Committee. Committee members represent Amneal...
Patent Office cancellation of PTE paves the way for potential launch of generic YASMIN products
Bayer Pharma Aktiengesellschaft [2022] APO 7Date:Venue:Delegate:7 February 2022Australian Patent OfficeKeith WraggBackground In our 2021 Patent Case summary, we reported on a...
Pearce IP BioBlast w/e 04 February 2022
01 Feb 22 | JAMP Pharma announced the creation of a new division BIOJAMP™ dedicated to biosimilars. The creation of this division was primarily made possible through JAMP’s...
Comments period on draft new National Medicines Policy extended – now closing on 2 March
Last week we alerted you to the release of a draft new National Medicines Policy (NMP) for public comment. The draft NMP was released by the National Medicines Policy Review...
No time to lose! Comments on the consultation draft of the new National Medicines Policy close on 16 February
On 2 February a draft of a new National Medicines Policy (NMP) was made available for public comment. The draft NMP was released by the National Medicines Policy Review...
Pearce IP BioBlast® f/e 31 January 2022
18 Jan 22 | Alvotech announced $21 million in additional commitments for private placement (PIPE) of Oaktree II common stock. Alvotech and Oaktree Acquisition Corp. II...
Pearce recognised as a World Leading IP Strategist by IAM Strategy 300
Pearce IP is proud to announce that Founding Principal and Executive Lawyer, Patent & Trade Mark Attorney, Naomi Pearce, has again been listed in the 2022 edition of IAM...
Pearce IP BioBlast® w/e 14 January 2022
10 Jan 22 | CA | Alvotech and JAMP Pharma announced that Health Canada has approved Simlandi (high-concentration, citrate-free biosimilar adalimumab). 11 Jan 22 | EU | Orion...
Pearce IP BioBlast® w/e 07 January 2022
30 Dec 21 | US | Biocon Biologics announced that the US Court of Appeals for the Federal Circuit Court has upheld the US Patent and Trademark Appeal Board’s decisions of...
Pfizer quest for Samsung Bioepis etanercept documents continues
Shortly before Christmas, the judgment handed down by Justice Burley on 18 November 2021 on a second preliminary discovery application made by Pfizer seeking documents from...
Pearce IP BioBlast® 31 December 2021
20 Dec 21 | US | Sandoz announced that it has submitted a BLA to the FDA for a proposed biosimilar trastuzumab. 20 Dec 21 | US | The FDA approved Eli Lilly’s Rezvlogar®...
PTE Alert (part 2): Bad Patent Term Extension Enables Generics to Avoid Preliminary Injunction in Australia
Newly appointed Justice Rofe delivered an early Christmas gift for generic and biosimilar companies in Australia in the Biogen v Pharmacor reasons delivered yesterday. We...
Pearce IP BioBlast® w/e 17 December 2021
11 Dec 21 | Samsung Bioepis announced that SB12 (proposed eculizumab biosimilar) met all the endpoints in a Ph I study. 13 Dec 21 | Xbrane Biopharma announced it is developing...
PTE Alert – interlocutory injunction refused in Tecfidera® dispute
In early November Pearce IP reported on a number of Federal Court decisions which appear to indicate flaws in the Australian Patent Office’s interpretation of the eligibility...
Vague proposals do not an inventor make
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Pearce IP BioBlast® w/e 10 December 2021
06 Dec 21 | AU | Australia’s TGA provisionally approved Celltrion’s Regkirona® (regdanvimab) for the treatment of adults with coronavirus who do not require supplemental oxygen...
Full Court finds another computer-implemented scheme unpatentable
Repipe Pty Ltd v Commissioner of Patents (No 3) [2021] FCA 31: Repipe Pty Ltd v Commissioner of Patents [2021] FCAFC 223
Date: 29 January 2021 Court: Federal Court of Australia Judge: McKerracher J Date: 08 December 2021 Court: Full Court of the Federal Court of Australia Judges: Perram, Nicholas...
Vague proposals do not an inventor make
Vehicle Monitoring Systems Pty Ltd v SARB Management Group Pty Ltd [2021] FCAFC 224
Date: 08 December 2021Court: Full Court of the Federal Court of AustraliaJudges: Nicholas, Yates and O'Bryan JJ Background Australian Patent Application 2013213708 (708...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.